Du benytter en nettleser vi ikke støtter. Se informasjon om nettlesere

. Referanser

Abdollah, F., Karnes, R. J., Suardi, N., Cozzarini, C., Gandaglia, G., Fossati, N., . . . Briganti, A. (2014). Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. Journal of Clinical Oncology, 32(35), 3939-3947. https://doi.org/10.1200/JCO.2013.54.7893

Abida, W., Cheng, M. L., Armenia, J., Middha, S., Autio, K. A., Vargas, H. A., . . . Scher, H. I. (2019). Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA oncology, 5(4), 471-478. https://doi.org/10.1001/jamaoncol.2018.5801

Ahmed, H. U., El-Shater Bosaily, A., Brown, L. C., Gabe, R., Kaplan, R., Parmar, M. K., . . . Emberton, M. (2017). Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet, 389(10071), 815-822. https://doi.org/10.1016/s0140-6736(16)32401-1

Aksnessæther, B. Y., Lund, J., Myklebust, T., Klepp, O. H., Skovlund, E., Roth Hoff, S., & Solberg, A. (2019). Second cancers in radically treated Norwegian prostate cancer patients. Acta Oncologica, 58(6), 838-844. https://doi.org/10.1080/0284186x.2019.1581377

Albertsen, P. C., Hanley, J. A., Gleason, D. F., & Barry, M. J. (1998). Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA, 280(11), 975-980. https://doi.org/10.1001/jama.280.11.975

Alsadius, D., Hedelin, M., Johansson, K. A., Pettersson, N., Wilderäng, U., Lundstedt, D., & Steineck, G. (2011). Tobacco smoking and long-lasting symptoms from the bowel and the anal-sphincter region after radiotherapy for prostate cancer. Radiotherapy and Oncology, 101(3), 495-501. https://doi.org/10.1016/j.radonc.2011.06.010

Amini, A., Jones, B. L., Yeh, N., Rusthoven, C. G., Armstrong, H., & Kavanagh, B. D. (2015). Survival Outcomes of Whole-Pelvic Versus Prostate-Only Radiation Therapy for High-Risk Prostate Cancer Patients With Use of the National Cancer Data Base. International Journal of Radiation Oncology, Biology, Physics, 93(5), 1052-1063. https://doi.org/10.1016/j.ijrobp.2015.09.006

Andreyev, H. J., Wotherspoon, A., Denham, J. W., & Hauer-Jensen, M. (2010). Defining pelvic-radiation disease for the survivorship era. Lancet Oncology, 11(4), 310-312. https://doi.org/10.1016/s1470-2045(10)70026-7

Association of the Nordic Cancer Registries. (2017). NORDCAN – Kreftstatistikk for de nordiske landene. Version 8.0. [database]. [s.l.]: Association of the Nordic Cancer Registries. Danish Cancer Society. Hentet 20. februar.2017, fra http://www-dep.iarc.fr/nordcan.htm

Attard, G., Murphy, L., Clarke, N. W., Cross, W., Jones, R. J., Parker, C. C., . . . James, N. D. (2022). Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet, 399(10323), 447-460. https://doi.org/10.1016/s0140-6736(21)02437-5

Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., . . . Tombal, B. (2014). Enzalutamide in metastatic prostate cancer before chemotherapy. New England Journal of Medicine, 371(5), 424-433. https://doi.org/10.1056/NEJMoa1405095

Bernard, J. R., Jr., Buskirk, S. J., Heckman, M. G., Diehl, N. N., Ko, S. J., Macdonald, O. K., . . . Pisansky, T. M. (2010). Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis. International Journal of Radiation Oncology, Biology, Physics, 76(3), 735-740. https://doi.org/10.1016/j.ijrobp.2009.02.049

Bolla, M., de Reijke, T. M., Van Tienhoven, G., Van den Bergh, A. C., Oddens, J., Poortmans, P. M., . . . Collette, L. (2009). Duration of androgen suppression in the treatment of prostate cancer. New England Journal of Medicine, 360(24), 2516-2527. https://doi.org/10.1056/NEJMoa0810095

Brand, D. H., Tree, A. C., Ostler, P., van der Voet, H., Loblaw, A., Chu, W., . . . van As, N. (2019). Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncology, 20(11), 1531-1543. https://doi.org/10.1016/s1470-2045(19)30569-8

Bray, F., Lortet-Tieulent, J., Ferlay, J., Forman, D., & Auvinen, A. (2010). Prostate cancer incidence and mortality trends in 37 European countries: an overview. European Journal of Cancer, 46(17), 3040-3052. https://doi.org/10.1016/j.ejca.2010.09.013

Brierley, J. D., Gospodarowicz, M. K., & Wittekind, C. (red.). (2017). TNM classification of malignant tumors (8. utg.). Hoboken, NJ: John Wiley & Sons, Inc.

Briganti, A., Larcher, A., Abdollah, F., Capitanio, U., Gallina, A., Suardi, N., . . . Montorsi, F. (2012). Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. European Urology, 61(3), 480-487. https://doi.org/10.1016/j.eururo.2011.10.044

Bul, M., van den Bergh, R. C., Zhu, X., Rannikko, A., Vasarainen, H., Bangma, C. H., . . . Roobol, M. J. (2012). Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU International, 110(11), 1672-1677. https://doi.org/10.1111/j.1464-410X.2012.11434.x

Burdett, S., Boevé, L. M., Ingleby, F. C., Fisher, D. J., Rydzewska, L. H., Vale, C. L., . . . Tierney, J. F. (2019). Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. European Urology, 76(1), 115-124. https://doi.org/10.1016/j.eururo.2019.02.003

Bøhn, S. H., Fosså, S. D., Wisløff, T., & Thorsen, L. (2019). Physical activity and associations with treatment-induced adverse effects among prostate cancer patients. Supportive Care in Cancer, 27(3), 1001-1011. https://doi.org/10.1007/s00520-018-4389-5

Carrie, C., Hasbini, A., de Laroche, G., Richaud, P., Guerif, S., Latorzeff, I., . . . Dussart, S. (2016). Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncology, 17(6), 747-756. https://doi.org/10.1016/S1470-2045(16)00111-X

Catton, C. N., Lukka, H., Gu, C. S., Martin, J. M., Supiot, S., Chung, P. W. M., . . . Levine, M. N. (2017). Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. Journal of Clinical Oncology, 35(17), 1884-1890. https://doi.org/10.1200/jco.2016.71.7397

Center, M. M., Jemal, A., Lortet-Tieulent, J., Ward, E., Ferlay, J., Brawley, O., & Bray, F. (2012). International variation in prostate cancer incidence and mortality rates. European Urology, 61(6), 1079-1092. https://doi.org/10.1016/j.eururo.2012.02.054

Chen, H., Ewing, C. M., Zheng, S., Grindedaal, E. M., Cooney, K. A., Wiley, K., . . . Isaacs, W. B. (2018). Genetic factors influencing prostate cancer risk in Norwegian men. Prostate, 78(3), 186-192. https://doi.org/10.1002/pros.23453

Cook, L. S., Goldoft, M., Schwartz, S. M., & Weiss, N. S. (1999). Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. Journal of Urology, 161(1), 152-155.

Cooperberg, M. R., Pasta, D. J., Elkin, E. P., Litwin, M. S., Latini, D. M., Du Chane, J., & Carroll, P. R. (2005). The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. Journal of Urology, 173(6), 1938-1942. https://doi.org/10.1097/01.ju.0000158155.33890.e7

Cornford, P., Bellmunt, J., Bolla, M., Briers, E., De Santis, M., Gross, T., . . . Mottet, N. (2017). EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. European Urology, 71(4), 630-642. https://doi.org/10.1016/j.eururo.2016.08.002

Cushman, T. R., Verma, V., Khairnar, R., Levy, J., Simone, C. B., 2nd, & Mishra, M. V. (2019). Stereotactic body radiation therapy for prostate cancer: systematic review and meta-analysis of prospective trials. Oncotarget, 10(54), 5660-5668. https://doi.org/10.18632/oncotarget.27177

D'Amico, A. V., Chen, M. H., Renshaw, A. A., Loffredo, M., & Kantoff, P. W. (2008). Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA, 299(3), 289-295. https://doi.org/10.1001/jama.299.3.289

Dall'Era, M. A., Albertsen, P. C., Bangma, C., Carroll, P. R., Carter, H. B., Cooperberg, M. R., . . . Soloway, M. S. (2012). Active surveillance for prostate cancer: a systematic review of the literature. European Urology, 62(6), 976-983. https://doi.org/10.1016/j.eururo.2012.05.072

de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J. P., Kocak, I., . . . Sartor, A. O. (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet, 376(9747), 1147-1154. https://doi.org/10.1016/s0140-6736(10)61389-x

de Wit, R., de Bono, J., Sternberg, C. N., Fizazi, K., Tombal, B., Wülfing, C., . . . Castellano, D. (2019). Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. New England Journal of Medicine, 381(26), 2506-2518. https://doi.org/10.1056/NEJMoa1911206

Dearnaley, D., Syndikus, I., Mossop, H., Khoo, V., Birtle, A., Bloomfield, D., . . . Hall, E. (2016). Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncology, 17(8), 1047-1060. https://doi.org/10.1016/s1470-2045(16)30102-4

Droz, J. P., Aapro, M., Balducci, L., Boyle, H., Van den Broeck, T., Cathcart, P., . . . Sugihara, T. (2014). Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncology, 15(9), e404-414. https://doi.org/10.1016/s1470-2045(14)70018-x

Eastham, J. A. (2007). Bone health in men receiving androgen deprivation therapy for prostate cancer. Journal of Urology, 177(1), 17-24. https://doi.org/10.1016/j.juro.2006.08.089

Edwards, S. M., Evans, D. G., Hope, Q., Norman, A. R., Barbachano, Y., Bullock, S., . . . Eeles, R. A. (2010). Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. British Journal of Cancer, 103(6), 918-924. https://doi.org/10.1038/sj.bjc.6605822

Edwards, S. M., Kote-Jarai, Z., Meitz, J., Hamoudi, R., Hope, Q., Osin, P., . . . Eeles, R. A. (2003). Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. American Journal of Human Genetics, 72(1), 1-12. https://doi.org/10.1086/345310

Eisenberger, M., Hardy-Bessard, A. C., Kim, C. S., Géczi, L., Ford, D., Mourey, L., . . . de Bono, J. (2017). Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m(2)) and the Currently Approved Dose (25 mg/m(2)) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. Journal of Clinical Oncology, 35(28), 3198-3206. https://doi.org/10.1200/jco.2016.72.1076

Epstein, J. I., Amin, M. B., Reuter, V. E., & Humphrey, P. A. (2017). Contemporary Gleason Grading of Prostatic Carcinoma: An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. American Journal of Surgical Pathology, 41(4), e1-e7. https://doi.org/10.1097/pas.0000000000000820

Epstein, J. I., Egevad, L., Amin, M. B., Delahunt, B., Srigley, J. R., & Humphrey, P. A. (2016). The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. American Journal of Surgical Pathology, 40(2), 244-252. https://doi.org/10.1097/pas.0000000000000530

Ewing, C. M., Ray, A. M., Lange, E. M., Zuhlke, K. A., Robbins, C. M., Tembe, W. D., . . . Cooney, K. A. (2012). Germline mutations in HOXB13 and prostate-cancer risk. New England Journal of Medicine, 366(2), 141-149. https://doi.org/10.1056/NEJMoa1110000

Extermann, M., Boler, I., Reich, R. R., Lyman, G. H., Brown, R. H., DeFelice, J., . . . Balducci, L. (2012). Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer, 118(13), 3377-3386. https://doi.org/10.1002/cncr.26646

Faria, R., Soares, M. O., Spackman, E., Ahmed, H. U., Brown, L. C., Kaplan, R., . . . Sculpher, M. J. (2018). Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS). European Urology, 73(1), 23-30. https://doi.org/10.1016/j.eururo.2017.08.018

Ficarra, V., Novara, G., Rosen, R. C., Artibani, W., Carroll, P. R., Costello, A., . . . Mottrie, A. (2012). Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. European Urology, 62(3), 405-417. https://doi.org/10.1016/j.eururo.2012.05.045

Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., . . . Goessl, C. (2011). Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet, 377(9768), 813-822. https://doi.org/10.1016/s0140-6736(10)62344-6

Fizazi, K., Foulon, S., Carles, J., Roubaud, G., McDermott, R., Fléchon, A., . . . Bossi, A. (2022). Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet, 399(10336), 1695-1707. https://doi.org/10.1016/s0140-6736(22)00367-1

Fizazi, K., Scher, H. I., Molina, A., Logothetis, C. J., Chi, K. N., Jones, R. J., . . . de Bono, J. S. (2012). Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncology, 13(10), 983-992. https://doi.org/10.1016/s1470-2045(12)70379-0

Fizazi, K., Shore, N. D., Tammela, T., Ulys, A., Vjaters, E., Polyakov, S., . . . Smith, M. R. (2020). Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC). Journal of Clinical Oncology, 38(15_suppl), 5514. https://doi.org/10.1200/JCO.2020.38.15_suppl.5514

Focal Prostate Ablation Versus Radical Prostatectomy (FARP). (2017-2024). [pågående studie]. (NCT03668652). Hentet fra https://clinicaltrials.gov/ct2/show/NCT03668652

Forskrift om prioritering av helsetjenester, rett til nødvendig helsehjelp fra spesialisthelsetjenesten, rett til behandling i utlandet og om klagenemnd (prioriteringsforskriften). (2000). FOR-2000-12-01-1208. Sist endret i FOR-2020-02-04-119 fra 01.03.2020. Hentet fra https://lovdata.no/dokument/SF/forskrift/2000-12-01-1208

Fossati, N., Willemse, P. M., Van den Broeck, T., van den Bergh, R. C. N., Yuan, C. Y., Briers, E., . . . Joniau, S. (2017). The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. European Urology, 72(1), 84-109. https://doi.org/10.1016/j.eururo.2016.12.003

Fransson, P., Nilsson, P., Gunnlaugsson, A., Beckman, L., Tavelin, B., Norman, D., . . . Widmark, A. (2021). Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. Lancet Oncology, 22(2), 235-245. https://doi.org/10.1016/s1470-2045(20)30581-7

Gandaglia, G., Trinh, Q. D., Hu, J. C., Schiffmann, J., Becker, A., Roghmann, F., . . . Abdollah, F. (2014). The impact of robot-assisted radical prostatectomy on the use and extent of pelvic lymph node dissection in the "post-dissemination" period. European Journal of Surgical Oncology, 40(9), 1080-1086. https://doi.org/10.1016/j.ejso.2013.12.016

Gjerset, G. M., Kiserud, C. E., Loge, J. H., Fosså, S. D., Wisløff, T., Gudbergsson, S. B., . . . Thorsen, L. (2019). Changes in fatigue, health-related quality of life and physical activity after a one-week educational program for cancer survivors. Acta Oncologica, 58(5), 682-689. https://doi.org/10.1080/0284186x.2018.1562210

Graff, J. N., & Beer, T. M. (2014). Pharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapy agents. Drugs and Aging, 31(12), 873-882. https://doi.org/10.1007/s40266-014-0224-y

Grindedal, E. M., Møller, P., Eeles, R., Stormorken, A. T., Bowitz-Lothe, I. M., Landrø, S. M., . . . Maehle, L. (2009). Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer Epidemiology, Biomarkers and Prevention, 18(9), 2460-2467. https://doi.org/10.1158/1055-9965.Epi-09-0058

Haglind, E., Carlsson, S., Stranne, J., Wallerstedt, A., Wilderäng, U., Thorsteinsdottir, T., . . . Steineck, G. (2015). Urinary Incontinence and Erectile Dysfunction After Robotic Versus Open Radical Prostatectomy: A Prospective, Controlled, Nonrandomised Trial. European Urology, 68(2), 216-225. https://doi.org/10.1016/j.eururo.2015.02.029

Hall, W. A., Paulson, E., Davis, B. J., Spratt, D. E., Morgan, T. M., Dearnaley, D., . . . Lawton, C. A. F. (2021). NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics, 109(1), 174-185. https://doi.org/10.1016/j.ijrobp.2020.08.034

Hamdy, F. C., Donovan, J. L., Lane, J. A., Mason, M., Metcalfe, C., Holding, P., . . . Neal, D. E. (2016). 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. New England Journal of Medicine, 375(15), 1415-1424. https://doi.org/10.1056/NEJMoa1606220

Haque, R., UlcickasYood, M., Xu, X., Cassidy-Bushrow, A. E., Tsai, H. T., Keating, N. L., . . . Potosky, A. L. (2017). Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study. British Journal of Cancer, 117(8), 1233-1240. https://doi.org/10.1038/bjc.2017.280

Helse- og omsorgsdepartementet. (2015). Nasjonal helse- og sykehusplan (2016−2019) (Meld. St. 11 (2015–2016)). Hentet fra https://www.regjeringen.no/contentassets/7b6ad7e0ef1a403d97958bcb34478609/no/pdfs/stm201520160011000dddpdfs.pdf

Helsedirektoratet. (2015). Kreftkirurgi i Norge (IS-2284). Oslo: Helsedirektoratet. Hentet fra https://www.helsedirektoratet.no/rapporter/kreftkirurgi-i-norge?download=false

Helsedirektoratet. (2. august 2018). Prostatakreft. I: Pakkeforløp for kreft: diagnoseveiledere. [nettdokument]. Oslo: Helsedirektoratet. Hentet 3. oktober 2022, fra https://www.helsedirektoratet.no/nasjonale-forlop/pakkeforlop-for-kreft-diagnoseveiledere/diagnoseveiledere#prostatakreft

Helsedirektoratet. (14. oktober 2019). Nasjonalt handlingsprogram for palliasjon i kreftomsorgen. [nettdokument]. Oslo: Helsedirektoratet. Hentet 3. november 2020, fra https://www.helsedirektoratet.no/retningslinjer/palliasjon-i-kreftomsorgen-handlingsprogram

Helsedirektoratet. (2020). Seneffekter etter kreftbehandling (IS-2872). Oslo: Helsedirektoratet. Hentet fra https://www.helsedirektoratet.no/rapporter/seneffekter-etter-kreftbehandling

Helsedirektoratet. (29. april 2022). Prostatakreft: pakkeforløp. [nettdokument]. Oslo: Helsedirektoratet. Hentet 03.10.2022, fra https://www.helsedirektoratet.no/pakkeforlop/prostatakreft

Himelstein, A. L., Foster, J. C., Khatcheressian, J. L., Roberts, J. D., Seisler, D. K., Novotny, P. J., . . . Shapiro, C. L. (2017). Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA, 317(1), 48-58. https://doi.org/10.1001/jama.2016.19425

Ilic, D., O'Connor, D., Green, S., & Wilt, T. J. (2011). Screening for prostate cancer: an updated Cochrane systematic review. BJU International, 107(6), 882-891. https://doi.org/10.1111/j.1464-410X.2010.10032.x

Ip, S., Dahabreh, I. J., Chung, M., Yu, W. W., Balk, E. M., Iovin, R. C., . . . Lau, J. (2011). An evidence review of active surveillance in men with localized prostate cancer. Evidence report/technology assessment, (204), 1-341.

Italiano, A., Ortholan, C., Oudard, S., Pouessel, D., Gravis, G., Beuzeboc, P., . . . Fizazi, K. (2009). Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. European Urology, 55(6), 1368-1375. https://doi.org/10.1016/j.eururo.2008.07.078

Jackson, W. C., Silva, J., Hartman, H. E., Dess, R. T., Kishan, A. U., Beeler, W. H., . . . Spratt, D. E. (2019). Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. International Journal of Radiation Oncology, Biology, Physics, 104(4), 778-789. https://doi.org/10.1016/j.ijrobp.2019.03.051

James, N. D., Spears, M. R., Clarke, N. W., Dearnaley, D. P., Mason, M. D., Parker, C. C., . . . Sydes, M. R. (2016). Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. JAMA oncology, 2(3), 348-357. https://doi.org/10.1001/jamaoncol.2015.4350

Joseph, D., Denham, J. W., Steigler, A., Lamb, D. S., Spry, N. A., Stanley, J., . . . Attia, J. (2020). Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial. International Journal of Radiation Oncology, Biology, Physics, 106(4), 693-702. https://doi.org/10.1016/j.ijrobp.2019.11.415

Karlsson, R., Aly, M., Clements, M., Zheng, L., Adolfsson, J., Xu, J., . . . Wiklund, F. (2014). A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. European Urology, 65(1), 169-176. https://doi.org/10.1016/j.eururo.2012.07.027

Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006). Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology, 24(27), 4448-4456. https://doi.org/10.1200/jco.2006.06.2497

Kellokumpu-Lehtinen, P. L., Harmenberg, U., Joensuu, T., McDermott, R., Hervonen, P., Ginman, C., . . . Joensuu, H. (2013). 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncology, 14(2), 117-124. https://doi.org/10.1016/s1470-2045(12)70537-5

Kishan, A. U., Cook, R. R., Ciezki, J. P., Ross, A. E., Pomerantz, M. M., Nguyen, P. L., . . . King, C. R. (2018). Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. JAMA, 319(9), 896-905. https://doi.org/10.1001/jama.2018.0587

Korfage, I. J., Essink-Bot, M. L., Borsboom, G. J., Madalinska, J. B., Kirkels, W. J., Habbema, J. D., . . . de Koning, H. J. (2005). Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. International Journal of Cancer, 116(2), 291-296. https://doi.org/10.1002/ijc.21043

Kote-Jarai, Z., Leongamornlert, D., Saunders, E., Tymrakiewicz, M., Castro, E., Mahmud, N., . . . Eeles, R. (2011). BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. British Journal of Cancer, 105(8), 1230-1234. https://doi.org/10.1038/bjc.2011.383

Kvåle, R., Myklebust, T., Engholm, G., Heinävaara, S., Wist, E., & Møller, B. (2017). Prostate and breast cancer in four Nordic countries: A comparison of incidence and mortality trends across countries and age groups 1975-2013. International Journal of Cancer, 141(11), 2228-2242. https://doi.org/10.1002/ijc.30924

Kyrdalen, A. E., Dahl, A. A., Hernes, E., Cvancarova, M., & Fosså, S. D. (2010). Fatigue in hormone-naïve prostate cancer patients treated with radical prostatectomy or definitive radiotherapy. Prostate Cancer and Prostatic Diseases, 13(2), 144-150. https://doi.org/10.1038/pcan.2009.61

Larsen, I. K. (red.). (2020). Cancer in Norway 2019: cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway. Hentet fra https://www.kreftregisteret.no/Generelt/Rapporter/Cancer-in-Norway/cancer-in-norway-2019/

Lawton, C. A., DeSilvio, M., Roach, M., Uhl, V., Kirsch, R., Seider, M., . . . Thomas, C. R. (2007). An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. International Journal of Radiation Oncology, Biology, Physics, 69(3), 646-655. https://doi.org/10.1016/j.ijrobp.2007.04.003

Lawton, C. A., Winter, K., Grignon, D., & Pilepich, M. V. (2005). Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. Journal of Clinical Oncology, 23(4), 800-807. https://doi.org/10.1200/jco.2005.08.141

Lehrer, E. J., Kishan, A. U., Yu, J. B., Trifiletti, D. M., Showalter, T. N., Ellis, R., & Zaorsky, N. G. (2020). Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials. Radiotherapy and Oncology, 148, 235-242. https://doi.org/10.1016/j.radonc.2020.04.037

Leongamornlert, D., Mahmud, N., Tymrakiewicz, M., Saunders, E., Dadaev, T., Castro, E., . . . Kote-Jarai, Z. (2012). Germline BRCA1 mutations increase prostate cancer risk. British Journal of Cancer, 106(10), 1697-1701. https://doi.org/10.1038/bjc.2012.146

Lorente, D., Omlin, A., Ferraldeschi, R., Pezaro, C., Perez, R., Mateo, J., . . . Attard, G. (2014). Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. British Journal of Cancer, 111(12), 2248-2253. https://doi.org/10.1038/bjc.2014.531

Lov om pasient- og brukerrettigheter (pasient- og brukerrettighetsloven). (1999). LOV-1999-07-02-63. Sist endret i LOV-2019-12-20-104 fra 01.03.2020. Hentet fra https://lovdata.no/dokument/NL/lov/1999-07-02-63

MacInnis, R. J., Severi, G., Baglietto, L., Dowty, J. G., Jenkins, M. A., Southey, M. C., . . . Giles, G. G. (2013). Population-based estimate of prostate cancer risk for carriers of the HOXB13 missense mutation G84E. PloS One, 8(2), e54727. https://doi.org/10.1371/journal.pone.0054727

Moch, H., Humphrey, P. A., & Ulbright, T. M. (2016). WHO Classification of Tumours of the Urinary System and Male Genital Organs (4. utg.). (WHO Classification of Tumours, Volume 8). Lyon: International Agency for Research on Cancer;.

Morash, C., Tey, R., Agbassi, C., Klotz, L., McGowan, T., Srigley, J., & Evans, A. (2015). Active surveillance for the management of localized prostate cancer: Guideline recommendations. Canadian Urological Association journal, 9(5-6), 171-178. https://doi.org/10.5489/cuaj.2806

Morris, W. J., Tyldesley, S., Rodda, S., Halperin, R., Pai, H., McKenzie, M., . . . Murray, N. (2017). Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics, 98(2), 275-285. https://doi.org/10.1016/j.ijrobp.2016.11.026

Moschini, M., Carroll, P. R., Eggener, S. E., Epstein, J. I., Graefen, M., Montironi, R., & Parker, C. (2017). Low-risk Prostate Cancer: Identification, Management, and Outcomes. European Urology, 72(2), 238-249. https://doi.org/10.1016/j.eururo.2017.03.009

Mosele, F., Remon, J., Mateo, J., Westphalen, C. B., Barlesi, F., Lolkema, M. P., . . . André, F. (2020). Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Annals of Oncology, 31(11), 1491-1505. https://doi.org/10.1016/j.annonc.2020.07.014

Mottet, N., Bellmunt, J., Bolla, M., Briers, E., Cumberbatch, M. G., De Santis, M., . . . Cornford, P. (2017). EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology, 71(4), 618-629. https://doi.org/10.1016/j.eururo.2016.08.003

Mottet, N., Cornford, P., van den Bergh, R. C. N., Briers, E., Santis, M. D., Fanti, S., . . . Wiegel, T. (2020). EAU - EANM - ESTRO - ESUR - SIOG Guidelines on Prostate Cancer (rev. utg.). Arnhem: European Association of Urology. Hentet fra https://uroweb.org/guideline/prostate-cancer/

Mulders, P. F., Molina, A., Marberger, M., Saad, F., Higano, C. S., Chi, K. N., . . . Fizazi, K. (2014). Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. European Urology, 65(5), 875-883. https://doi.org/10.1016/j.eururo.2013.09.005

Murthy, V., Maitre, P., Kannan, S., Panigrahi, G., Krishnatry, R., Bakshi, G., . . . Mahantshetty, U. (2021). Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial. Journal of Clinical Oncology, 39(11), 1234-1242. https://doi.org/10.1200/jco.20.03282

Nasjonalt kvalitetsregiser for prostatakreft. (2017). Årsrapport 2016 med resultater og forbedringstiltak. Oslo: Kreftregisteret. Hentet fra https://www.kreftregisteret.no/globalassets/publikasjoner-og-rapporter/arsrapporter/publisert-2017/arsrapport-2016_prostatakreft.pdf

National Comprehensive Cancer Network. (2018). NCCN Guidelines Prostate Cancer. Plymouth Meeting, PA: NCCN.

Norsk revmatologisk forening. (01. mai 2022). Osteoporose. Versjon 0.12. I: Revmatologi (NRF): nasjonal veileder. [nettdokument]. Oslo: Norsk revmatologisk forening. Hentet 30. september 2022, fra https://metodebok.no/index.php?action=topic&item=AtEEtJ7q

Novara, G., Ficarra, V., Mocellin, S., Ahlering, T. E., Carroll, P. R., Graefen, M., . . . Wilson, T. G. (2012a). Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. European Urology, 62(3), 382-404. https://doi.org/10.1016/j.eururo.2012.05.047

Novara, G., Ficarra, V., Rosen, R. C., Artibani, W., Costello, A., Eastham, J. A., . . . Wilson, T. G. (2012b). Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. European Urology, 62(3), 431-452. https://doi.org/10.1016/j.eururo.2012.05.044

Odisho, A. Y., Washington, S. L., 3rd, Meng, M. V., Cowan, J. E., Simko, J. P., & Carroll, P. R. (2013). Benign prostate glandular tissue at radical prostatectomy surgical margins. Urology, 82(1), 154-159. https://doi.org/10.1016/j.urology.2012.12.063

Ost, P., Reynders, D., Decaestecker, K., Fonteyne, V., Lumen, N., De Bruycker, A., . . . De Meerleer, G. (2018). Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. Journal of Clinical Oncology, 36(5), 446-453. https://doi.org/10.1200/jco.2017.75.4853

Oudard, S., Fizazi, K., Sengeløv, L., Daugaard, G., Saad, F., Hansen, S., . . . Sartor, O. (2017). Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. Journal of Clinical Oncology, 35(28), 3189-3197. https://doi.org/10.1200/jco.2016.72.1068

Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., . . . Sartor, O. (2013). Alpha emitter radium-223 and survival in metastatic prostate cancer. New England Journal of Medicine, 369(3), 213-223. https://doi.org/10.1056/NEJMoa1213755

Parker, C. C., James, N. D., Brawley, C. D., Clarke, N. W., Hoyle, A. P., Ali, A., . . . Sydes, M. R. (2018). Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet, 392(10162), 2353-2366. https://doi.org/10.1016/s0140-6736(18)32486-3

Penson, D. F., & Litwin, M. S. (2003). Quality of life after treatment for prostate cancer. Current urology reports, 4(3), 185-195. https://doi.org/10.1007/s11934-003-0068-1

Petersen, L. J., Nielsen, J. B., Dettmann, K., Fisker, R. V., Haberkorn, U., Stenholt, L., & Zacho, H. D. (2017). (68)Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level <2 ng/ml: Two case reports and a literature review. Molecular and clinical oncology, 7(1), 67-72. https://doi.org/10.3892/mco.2017.1280

Petrylak, D. P., Tangen, C. M., Hussain, M. H., Lara, P. N., Jr., Jones, J. A., Taplin, M. E., . . . Crawford, E. D. (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New England Journal of Medicine, 351(15), 1513-1520. https://doi.org/10.1056/NEJMoa041318

Pfister, D., Bolla, M., Briganti, A., Carroll, P., Cozzarini, C., Joniau, S., . . . Zelefsky, M. J. (2014). Early salvage radiotherapy following radical prostatectomy. European Urology, 65(6), 1034-1043. https://doi.org/10.1016/j.eururo.2013.08.013

Phillips, R., Shi, W. Y., Deek, M., Radwan, N., Lim, S. J., Antonarakis, E. S., . . . Tran, P. T. (2020). Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA oncology, 6(5), 650-659. https://doi.org/10.1001/jamaoncol.2020.0147

Pillay, B., Wootten, A. C., Crowe, H., Corcoran, N., Tran, B., Bowden, P., . . . Costello, A. J. (2016). The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. Cancer Treatment Reviews, 42, 56-72. https://doi.org/10.1016/j.ctrv.2015.11.007

Popiolek, M., Rider, J. R., Andrén, O., Andersson, S. O., Holmberg, L., Adami, H. O., & Johansson, J. E. (2013). Natural history of early, localized prostate cancer: a final report from three decades of follow-up. European Urology, 63(3), 428-435. https://doi.org/10.1016/j.eururo.2012.10.002

Resnick, M. J., Koyama, T., Fan, K. H., Albertsen, P. C., Goodman, M., Hamilton, A. S., . . . Penson, D. F. (2013). Long-term functional outcomes after treatment for localized prostate cancer. New England Journal of Medicine, 368(5), 436-445. https://doi.org/10.1056/NEJMoa1209978

Rider, J. R., Sandin, F., Andrén, O., Wiklund, P., Hugosson, J., & Stattin, P. (2013). Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. European Urology, 63(1), 88-96. https://doi.org/10.1016/j.eururo.2012.08.001

Roach, M., 3rd, Hanks, G., Thames, H., Jr., Schellhammer, P., Shipley, W. U., Sokol, G. H., & Sandler, H. (2006). Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. International Journal of Radiation Oncology, Biology, Physics, 65(4), 965-974. https://doi.org/10.1016/j.ijrobp.2006.04.029

Rowe, S. P., Pienta, K. J., Pomper, M. G., & Gorin, M. A. (2018). PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies. European Urology, 73(4), 485-487. https://doi.org/10.1016/j.eururo.2017.10.027

Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F., Sternberg, C. N., . . . Rathkopf, D. E. (2015). Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncology, 16(2), 152-160. https://doi.org/10.1016/s1470-2045(14)71205-7

Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., . . . Krause, B. J. (2021). Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine, 385(12), 1091-1103. https://doi.org/10.1056/NEJMoa2107322

Sathianathen, N. J., Philippou, Y. A., Kuntz, G. M., Konety, B. R., Gupta, S., Lamb, A. D., & Dahm, P. (2018). Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer. Cochrane Database of Systematic Reviews, 10(10), CD012816. https://doi.org/10.1002/14651858.CD012816.pub2

Scher, H. I., Fizazi, K., Saad, F., Taplin, M. E., Sternberg, C. N., Miller, K., . . . de Bono, J. S. (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine, 367(13), 1187-1197. https://doi.org/10.1056/NEJMoa1207506

Schroder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L., Zappa, M., Nelen, V., . . . Investigators, E. (2014). Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet, 384(9959), 2027-2035. https://doi.org/10.1016/S0140-6736(14)60525-0

Shipley, W. U., Seiferheld, W., Lukka, H. R., Major, P. P., Heney, N. M., Grignon, D. J., . . . RTOG, N. R. G. O. (2017). Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. New England Journal of Medicine, 376(5), 417-428. https://doi.org/10.1056/NEJMoa1607529

Shore, N. D., Chowdhury, S., Villers, A., Klotz, L., Siemens, D. R., Phung, D., . . . Heidenreich, A. (2016). Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncology, 17(2), 153-163. https://doi.org/10.1016/s1470-2045(15)00518-5

Siegmann, A., Bottke, D., Faehndrich, J., Lohm, G., Miller, K., Bartkowiak, D., . . . Hinkelbein, W. (2011). Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival: results of a retrospective study. Strahlentherapie und Onkologie, 187(8), 467-472. https://doi.org/10.1007/s00066-011-2229-3

Simpkin, A. J., Tilling, K., Martin, R. M., Lane, J. A., Hamdy, F. C., Holmberg, L., . . . Donovan, J. L. (2015). Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer. European Urology, 67(6), 993-1005. https://doi.org/10.1016/j.eururo.2015.01.004

Small, E. J., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B. A., Graff, J. N., . . . Smith, M. R. (2020). Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). Journal of Clinical Oncology, 38(15_suppl), 5516. https://doi.org/10.1200/JCO.2020.38.15_suppl.5516

Smith, M. R., Halabi, S., Ryan, C. J., Hussain, A., Vogelzang, N., Stadler, W., . . . Small, E. J. (2014). Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). Journal of Clinical Oncology, 32(11), 1143-1150. https://doi.org/10.1200/jco.2013.51.6500

Smith, M. R., Hussain, M., Saad, F., Fizazi, K., Sternberg, C. N., Crawford, E. D., . . . Tombal, B. (2022). Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. New England Journal of Medicine, 386(12), 1132-1142. https://doi.org/10.1056/NEJMoa2119115

Steineck, G., Bjartell, A., Hugosson, J., Axén, E., Carlsson, S., Stranne, J., . . . Wiklund, P. (2015). Degree of preservation of the neurovascular bundles during radical prostatectomy and urinary continence 1 year after surgery. European Urology, 67(3), 559-568. https://doi.org/10.1016/j.eururo.2014.10.011

Stensvold, A., Dahl, A. A., Brennhovd, B., Småstuen, M. C., Fosså, S. D., Lilleby, W., . . . Smeland, S. (2013). Bother problems in prostate cancer patients after curative treatment. Urologic Oncology, 31(7), 1067-1078. https://doi.org/10.1016/j.urolonc.2011.12.020

Sternberg, C. N., Fizazi, K., Saad, F., Shore, N. D., Giorgi, U. D., Penson, D. F., . . . Hussain, M. H. A. (2020). Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). Journal of Clinical Oncology, 38(15_suppl), 5515. https://doi.org/10.1200/JCO.2020.38.15_suppl.5515

Sterzing, F., Kratochwil, C., Fiedler, H., Katayama, S., Habl, G., Kopka, K., . . . Giesel, F. L. (2016). (68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 43(1), 34-41. https://doi.org/10.1007/s00259-015-3188-1

Stish, B. J., Pisansky, T. M., Harmsen, W. S., Davis, B. J., Tzou, K. S., Choo, R., & Buskirk, S. J. (2016). Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer. Journal of Clinical Oncology, 34(32), 3864-3871. https://doi.org/10.1200/JCO.2016.68.3425

Surgery Versus Radiotherapy for Locally Advanced Prostate Cancer (SPCG-15). (2017-2027). [pågående studie]. (NCT02102477). Hentet fra https://clinicaltrials.gov/ct2/show/NCT02102477

Sweeney, C. J., Chen, Y. H., Carducci, M., Liu, G., Jarrard, D. F., Eisenberger, M., . . . DiPaola, R. S. (2015). Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. New England Journal of Medicine, 373(8), 737-746. https://doi.org/10.1056/NEJMoa1503747

Syse, A., Pham, D. Q., & Keilman, N. (2016). Befolkningsframskrivinger 2016 - 2100: Dødelighet og levealder. Økonomiske analyser, (3), 25-36.

Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., . . . Chen, B. (2002). A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Journal of the National Cancer Institute, 94(19), 1458-1468. https://doi.org/10.1093/jnci/94.19.1458

Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., . . . Eisenberger, M. A. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine, 351(15), 1502-1512. https://doi.org/10.1056/NEJMoa040720

Thorsen, L., Nilsen, T. S., Raastad, T., Courneya, K. S., Skovlund, E., & Fosså, S. D. (2012). A randomized controlled trial on the effectiveness of strength training on clinical and muscle cellular outcomes in patients with prostate cancer during androgen deprivation therapy: rationale and design. BMC Cancer, 12, 123. https://doi.org/10.1186/1471-2407-12-123

Thostrup, M., Thomsen, F. B., Iversen, P., & Brasso, K. (2018). Active surveillance for localized prostate cancer: update of a prospective single-center cohort. Scandinavian Journal of Urology, 52(1), 14-19. https://doi.org/10.1080/21681805.2017.1380697

Tikkinen, K. A. O., Cartwright, R., Gould, M. K., Naspro, R., Novara, G., Sandset, P. M., . . . Guyatt, G. H. (2018). EAU Guidelines on Thromboprophylaxis in Urological Surgery. Arnhem: European Association of Urology. Hentet fra https://uroweb.org/guideline/thromboprophylaxis/

Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., & Jemal, A. (2015). Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 65(2), 87-108. https://doi.org/10.3322/caac.21262

Toussi, A., Stewart-Merrill, S. B., Boorjian, S. A., Psutka, S. P., Thompson, R. H., Frank, I., . . . Karnes, R. J. (2016). Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression? Journal of Urology, 195(6), 1754-1759. https://doi.org/10.1016/j.juro.2015.12.075

van As, N., & Tree, A. (2020). The PACE Trial (Prostate Advances in Comparative Evidence): International randomised study of prostatectomy vs stereotactic body radiotherapy (SBRT) and conventional radiotherapy vs SBRT for early stage organ-confined prostate cancer: radiotherapy plannng and delivery guidelines (PACE-A and PACE-C) (Version: 2.0 utg.). London: Royal Marsden Hospital. Hentet fra https://d1ijoxngr27nfi.cloudfront.net/docs/default-source/default-document-library/pace_c_rtqaguidelines_v2-0-(04-march-2020).pdf?sfvrsn=dd202169_4

van den Bergh, R. C., Albertsen, P. C., Bangma, C. H., Freedland, S. J., Graefen, M., Vickers, A., & van der Poel, H. G. (2013). Timing of curative treatment for prostate cancer: a systematic review. European Urology, 64(2), 204-215. https://doi.org/10.1016/j.eururo.2013.02.024

Van den Broeck, T., van den Bergh, R. C. N., Arfi, N., Gross, T., Moris, L., Briers, E., . . . Mottet, N. (2019). Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. European Urology, 75(6), 967-987. https://doi.org/10.1016/j.eururo.2018.10.011

van der Wielen, G. J., Mulhall, J. P., & Incrocci, L. (2007). Erectile dysfunction after radiotherapy for prostate cancer and radiation dose to the penile structures: a critical review. Radiotherapy and Oncology, 84(2), 107-113. https://doi.org/10.1016/j.radonc.2007.07.018

Vatne, K., Stensvold, A., Myklebust, T., Møller, B., Svindland, A., Kvåle, R., & Fosså, S. D. (2017). Pre- and post-prostatectomy variables associated with pelvic post-operative radiotherapy in prostate cancer patients: a national registry-based study. Acta Oncologica, 56(10), 1295-1301. https://doi.org/10.1080/0284186x.2017.1314006

Venkitaraman, R., Lorente, D., Murthy, V., Thomas, K., Parker, L., Ahiabor, R., . . . Parker, C. (2015). A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. European Urology, 67(4), 673-679. https://doi.org/10.1016/j.eururo.2014.10.004

Ventimiglia, E., Seisen, T., Abdollah, F., Briganti, A., Fonteyne, V., James, N., . . . Cheng, L. (2019). A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer. European Urology Oncology, 2(3), 294-301. https://doi.org/10.1016/j.euo.2019.02.001

Viste, E., Vinje, C. A., Lid, T. G., Skeie, S., Evjen-Olsen, Ø., Nordström, T., . . . Kjosavik, S. R. (2020). Effects of replacing PSA with Stockholm3 for diagnosis of clinically significant prostate cancer in a healthcare system - the Stavanger experience. Scandinavian Journal of Primary Health Care, 38(3), 315-322. https://doi.org/10.1080/02813432.2020.1802139

Wallerstedt, A., Tyritzis, S. I., Thorsteinsdottir, T., Carlsson, S., Stranne, J., Gustafsson, O., . . . Haglind, E. (2015). Short-term results after robot-assisted laparoscopic radical prostatectomy compared to open radical prostatectomy. European Urology, 67(4), 660-670. https://doi.org/10.1016/j.eururo.2014.09.036

Walz, J., Epstein, J. I., Ganzer, R., Graefen, M., Guazzoni, G., Kaouk, J., . . . Artibani, W. (2016). A Critical Analysis of the Current Knowledge of Surgical Anatomy of the Prostate Related to Optimisation of Cancer Control and Preservation of Continence and Erection in Candidates for Radical Prostatectomy: An Update. European Urology, 70(2), 301-311. https://doi.org/10.1016/j.eururo.2016.01.026

Widmark, A., Gunnlaugsson, A., Beckman, L., Thellenberg-Karlsson, C., Hoyer, M., Lagerlund, M., . . . Nilsson, P. (2019). Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet, 394(10196), 385-395. https://doi.org/10.1016/s0140-6736(19)31131-6

Widmark, A., Klepp, O., Solberg, A., Damber, J. E., Angelsen, A., Fransson, P., . . . Fosså, S. D. (2009). Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet, 373(9660), 301-308. https://doi.org/10.1016/s0140-6736(08)61815-2

Win, A. K., Lindor, N. M., Young, J. P., Macrae, F. A., Young, G. P., Williamson, E., . . . Jenkins, M. A. (2012). Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. Journal of the National Cancer Institute, 104(18), 1363-1372. https://doi.org/10.1093/jnci/djs351

Wood, L. J., Nail, L. M., Gilster, A., Winters, K. A., & Elsea, C. R. (2006). Cancer chemotherapy-related symptoms: evidence to suggest a role for proinflammatory cytokines. Oncology Nursing Forum, 33(3), 535-542. https://doi.org/10.1188/06.Onf.535-542

Yu, E. Y., Gillessen, S., & Mottet, N. (2019). What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy? National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations. European urology focus, 5(2), 162-164. https://doi.org/10.1016/j.euf.2018.09.015

Zhang, L., Tang, M., Chen, S., Lei, X., Zhang, X., & Huan, Y. (2017). A meta-analysis of use of Prostate Imaging Reporting and Data System Version 2 (PI-RADS V2) with multiparametric MR imaging for the detection of prostate cancer. European Radiology, 27(12), 5204-5214. https://doi.org/10.1007/s00330-017-4843-7

Østerø Í Jákupsstovu, J., & Brodersen, J. (2018). Do men with lower urinary tract symptoms have an increased risk of advanced prostate cancer? BMJ, 361, k1202. https://doi.org/10.1136/bmj.k1202

Sist faglig oppdatert: 14. oktober 2022